Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2448-2455

  Berchuck, Andrew ^a   Iversen, Edwin S ^a   Luo, Jingqin ^a   Clarke, Jennifer P ^a   Horne, Hisani ^a   Levine, Douglas A ^b   Boyd, Jeff ^b   Alonso, Miguel A ^c   Secord, Angeles Alvarez ^a   Bernardini, Marcus Q ^a   Barnett, Jason C ^a   Boren, Todd ^c   Murphy, Susan K ^a   Dressman, Holly K ^a   Marks, Jeffrey R ^a   Lancaster, Johnathan M ^d  

^a DUKE UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; EARLY CANCER; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SURVIVAL TIME;

FEMALE; GENE EXPRESSION PROFILING; HUMANS; MEMBRANE GLYCOPROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, INTERLEUKIN-1;

EID: 65249155369     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2430     Document Type: Article

References (30)

1. Hoskins WJ, McGuireWP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with subop- timal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
2. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol 2001;19:1901 -5.
3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.
4. Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin Oncol 2000;27:8-10.
5. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23:7919-26.
6. BonomeT, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65:10602-12.
7. Gilks CB, Vanderhyden BC, Zhu S, van de RM, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684-94.
8. Sieben NL, Oosting J, Flanagan AM, et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J Clin Oncol 2005;23:7257-64.
9. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expressionin ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
10. Zorn KK, BonomeT, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30.
11. ShridharV, Lee J, Pandita A, et al. Genetic analysis of early-versus late-stage ovarian tumors. Cancer Res 2001;61:5895-904.
12. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686-96.
13. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
14. Tothill RW,TinkerAV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14: 5198-208.
15. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
16. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-25.
17. Benito M, Parker J, Du Q, et al. Adjustment of systematic microarray data biases. Bioinformatics 2004; 20:105-14.
18. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, Gabrielson E. A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 2004;10:2922-7.
19. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007;8:118-27.
20. Martin-Belmonte F, Kremer L, AlbarJP, Marazuela M, Alonso MA. Expression of the MAL gene in the thyroid: the MAL proteolipid, acomponent of glycolipid-enriched membranes, is apically distributed in thyroid follicles. Endocrinology 1998;139:2077-84.
21. Shih I, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 2005;11:7273-9.
22. Havrilesky L, Darcy M, Hamdan H, et al. Prognostic significance of p53 mutation and p53 overex-pression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2003;21:3814-25.
23. Leitao MM, Soslow RA, Baergen RN, Olvera N, Arroyo C, Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 2004;93:301 -6.
24. Spentzos D, Levine DA, KoliaS, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005;23: 7911-8.
25. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11:6300-10.
26. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005;11:2149-55.
27. Horne HN, Lee PS, Murphy SK, et al. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res 2009;7:199-209.
28. Potti A, Nevins JR. Utilization of genomic signatures to direct use of primary chemotherapy. Curr Opin Genet Dev 2008;18:62-7.
29. Garzetti GG,CiavattiniA,GoteriG,et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 1995; 56:169-74.
30. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38.